ALEMBIC PHARMA | VENUS REMEDIES | ALEMBIC PHARMA/ VENUS REMEDIES |
|||
---|---|---|---|---|---|
P/E (TTM) | x | 16.6 | -7.5 | - | View Chart |
P/BV | x | 6.6 | 0.5 | 1,323.3% | View Chart |
Dividend Yield | % | 0.6 | 0.0 | - |
![]() ![]() |
EQUITY SHARE DATA | |||||
---|---|---|---|---|---|
ALEMBIC PHARMA Mar-19 |
VENUS REMEDIES Mar-18 |
ALEMBIC PHARMA/ VENUS REMEDIES |
5-Yr Chart Click to enlarge
|
||
High | Rs | 664 | 126 | 527.4% | |
Low | Rs | 412 | 61 | 675.0% | |
Sales per share (Unadj.) | Rs | 208.7 | 301.8 | 69.2% | |
Earnings per share (Unadj.) | Rs | 31.0 | -24.9 | -124.6% | |
Cash flow per share (Unadj.) | Rs | 37.1 | 2.5 | 1,458.4% | |
Dividends per share (Unadj.) | Rs | 5.50 | 0 | - | |
Dividend yield (eoy) | % | 1.0 | 0 | - | |
Book value per share (Unadj.) | Rs | 144.2 | 293.3 | 49.2% | |
Shares outstanding (eoy) | m | 188.52 | 12.34 | 1,527.7% | |
Bonus/Rights/Conversions | - | - | - | ||
Price / Sales ratio | x | 2.6 | 0.3 | 832.3% | |
Avg P/E ratio | x | 17.4 | -3.8 | -461.8% | |
P/CF ratio (eoy) | x | 14.5 | 36.7 | 39.5% | |
Price / Book Value ratio | x | 3.7 | 0.3 | 1,170.6% | |
Dividend payout | % | 17.7 | 0 | - | |
Avg Mkt Cap | Rs m | 101,461 | 1,154 | 8,793.8% | |
No. of employees | `000 | NA | 0.9 | 0.0% | |
Total wages/salary | Rs m | 7,467 | 393 | 1,899.5% | |
Avg. sales/employee | Rs Th | NM | 4,026.1 | - | |
Avg. wages/employee | Rs Th | NM | 425.0 | - | |
Avg. net profit/employee | Rs Th | NM | -331.8 | - |
INCOME DATA | |||||
---|---|---|---|---|---|
Net Sales | Rs m | 39,347 | 3,724 | 1,056.5% | |
Other income | Rs m | 94 | 23 | 416.9% | |
Total revenues | Rs m | 39,441 | 3,747 | 1,052.7% | |
Gross profit | Rs m | 8,736 | 395 | 2,212.7% | |
Depreciation | Rs m | 1,152 | 338 | 340.6% | |
Interest | Rs m | 184 | 354 | 52.0% | |
Profit before tax | Rs m | 7,493 | -275 | -2,721.8% | |
Minority Interest | Rs m | 11 | 0 | - | |
Prior Period Items | Rs m | -93 | 0 | - | |
Extraordinary Inc (Exp) | Rs m | 0 | 0 | - | |
Tax | Rs m | 1,568 | 32 | 4,960.4% | |
Profit after tax | Rs m | 5,844 | -307 | -1,904.1% | |
Gross profit margin | % | 22.2 | 10.6 | 209.4% | |
Effective tax rate | % | 20.9 | -11.5 | -182.2% | |
Net profit margin | % | 14.9 | -8.2 | -180.2% |
BALANCE SHEET DATA | |||||
---|---|---|---|---|---|
Current assets | Rs m | 19,577 | 2,638 | 742.2% | |
Current liabilities | Rs m | 14,896 | 2,305 | 646.4% | |
Net working cap to sales | % | 11.9 | 8.9 | 133.0% | |
Current ratio | x | 1.3 | 1.1 | 114.8% | |
Inventory Days | Days | 90 | 135 | 66.3% | |
Debtors Days | Days | 45 | 46 | 97.9% | |
Net fixed assets | Rs m | 27,097 | 4,871 | 556.3% | |
Share capital | Rs m | 377 | 123 | 305.5% | |
"Free" reserves | Rs m | 26,811 | 3,496 | 767.0% | |
Net worth | Rs m | 27,188 | 3,619 | 751.2% | |
Long term debt | Rs m | 4,993 | 1,374 | 363.3% | |
Total assets | Rs m | 47,778 | 7,509 | 636.3% | |
Interest coverage | x | 41.7 | 0.2 | 18,702.5% | |
Debt to equity ratio | x | 0.2 | 0.4 | 48.4% | |
Sales to assets ratio | x | 0.8 | 0.5 | 166.0% | |
Return on assets | % | 12.6 | 0.6 | 1,998.5% | |
Return on equity | % | 21.5 | -8.5 | -253.5% | |
Return on capital | % | 23.6 | 1.6 | 1,491.8% | |
Exports to sales | % | 0 | 0 | - | |
Imports to sales | % | 0 | 13.9 | 0.0% | |
Exports (fob) | Rs m | NA | NA | - | |
Imports (cif) | Rs m | NA | 517 | 0.0% | |
Fx inflow | Rs m | 19,453 | 0 | - | |
Fx outflow | Rs m | 6,065 | 517 | 1,174.2% | |
Net fx | Rs m | 13,388 | -517 | -2,592.0% |
CASH FLOW | |||||
---|---|---|---|---|---|
From Operations | Rs m | 8,120 | 514 | 1,578.5% | |
From Investments | Rs m | -7,556 | -123 | 6,138.1% | |
From Financial Activity | Rs m | 590 | -387 | -152.5% | |
Net Cashflow | Rs m | 1,153 | 4 | 27,459.5% |
Indian Promoters | % | 74.1 | 32.9 | 225.6% | |
Foreign collaborators | % | 0.0 | 0.0 | - | |
Indian inst/Mut Fund | % | 2.9 | 0.2 | 1,611.1% | |
FIIs | % | 9.1 | 0.6 | 1,569.0% | |
ADR/GDR | % | 0.0 | 0.0 | - | |
Free float | % | 13.9 | 66.4 | 20.9% | |
Shareholders | 49,328 | 20,121 | 245.2% | ||
Pledged promoter(s) holding | % | 0.0 | 36.4 | - |
Compare ALEMBIC PHARMA With: NATCO PHARMA FRESENIUS KABI ONCO. FDC TORRENT PHARMA STRIDES PHARMA SCIENCE
Compare ALEMBIC PHARMA With: ADCOCK INGRAM (S. Africa) MYLAN (US) ACTAVIS (US) TEVA PHARMA (Israel)
Share markets in India are presently trading on a negative note. The BSE Sensex is trading down by 553 points, down 1.1% at 47,794 levels.
For the quarter ended December 2020, ALEMBIC PHARMA has posted a net profit of Rs 3 bn (up 13.8% YoY). Sales on the other hand came in at Rs 13 bn (up 8.7% YoY). Read on for a complete analysis of ALEMBIC PHARMA's quarterly results.
For the quarter ended September 2020, ALEMBIC PHARMA has posted a net profit of Rs 3 bn (up 30.0% YoY). Sales on the other hand came in at Rs 15 bn (up 17.4% YoY). Read on for a complete analysis of ALEMBIC PHARMA's quarterly results.
For the quarter ended December 2019, ALEMBIC PHARMA has posted a net profit of Rs 2 bn (up 33.3% YoY). Sales on the other hand came in at Rs 12 bn (up 18.8% YoY). Read on for a complete analysis of ALEMBIC PHARMA's quarterly results.
For the quarter ended September 2019, ALEMBIC PHARMA has posted a net profit of Rs 3 bn (up 25.2% YoY). Sales on the other hand came in at Rs 12 bn (up 10.1% YoY). Read on for a complete analysis of ALEMBIC PHARMA's quarterly results.
For the quarter ended June 2019, ALEMBIC PHARMA has posted a net profit of Rs 1 bn (up 36.4% YoY). Sales on the other hand came in at Rs 9 bn (up 10.0% YoY). Read on for a complete analysis of ALEMBIC PHARMA's quarterly results.
More Views on NewsIn this video, I'll show you why it might be the right time to take money of the table in pharma stocks.
The pandemic failed to thwart Richa's investing success formula for 2020.
In this video, I'll show you a crucial chart that you need to check before you decide to sell any stock or index.
Our ace stock picker is ready to capitalise on a big growth opportunity.
More